Trial Profile

A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Citarinostat (CC-96241), a Histone Deacetylase Inhibitor (HDAC) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Citarinostat (Primary) ; Lenalidomide (Primary) ; Poly ICLC (Primary) ; PVX 410 (Primary)
Indications Smoldering multiple myeloma
Focus Adverse reactions

10 Sep 2025 Planned End Date changed from 15 Sep 2024 to 15 Sep 2026.
10 Sep 2025 Planned primary completion date changed from 15 Sep 2024 to 15 Sep 2025.
12 Apr 2024 Planned End Date changed from 1 Jun 2023 to 15 Sep 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com